This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.
In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.
A health outcomes analysis of 419 patients with multiple myeloma sought to determine if cipro-doxy was more effective than cipro alone in reducing the incidence of neutropenic fever and infections, both significant causes of morbidity and death for these patients.
A retrospective study evaluated timing, frequency, dosing, and other factors related to bisphosphonate therapy in patients with multiple myeloma.
Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.
What are the common oncologic emergencies seen in patients with MM?
ADAR1 knockdown reduces regeneration of high-risk multiple myeloma in patient-derived xenografts
For this meta-analysis and systematic review, investigators compiled phase 1 to 3 prospective clinical trials of carfilzomib therapy for patients with MM that had evaluable toxic effects data.
An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.
A retrospective study, presented at ASH 2017, determined the effectiveness of aspirin in reducing risk of VTE in patients with multiple myeloma at high risk of developing VTE.
A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.
Breakthrough Therapy Designation was granted for bb2121, a novel CAR T-cell therapy indicated for patients with multiple myeloma who have undergone previous treatments.
In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.
The use of flow cytometry has demonstrated usefulness in multiple myeloma recurrence assessment.
Researchers randomly assigned 478 patients with R/R MM to receive carfilzomib 70 mg/m2 once weekly plus dexamethasone or carfilzomib 27 mg/m2 twice weekly plus dexamethasone.
A first-reported case of simultaneous intracranial plasmacytoma and malignant pericardial effusion in a woman with relapsed multiple myeloma previously treated with chemotherapy and allogenic HSCT is described.
Patients with multiple myeloma treated with daratumumab who experience IRRs may easily be managed by administering pre-infusion and postinfusion medications, investigators reported in a presentation at ESMO 2017 Congress.
The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.
Time to disease progression was significantly prolonged in patients with multiple myeloma who received lenalidomide therapy after ASCT.
[Cancer Management and Research] The research examines the various combination strategies for the treatment of multiple myeloma, with a focus on the use of elotuzumab.
Comparison study demonstrates early response and survival benefits of VTD, VTDC, and TAD regimens in transplant-eligible patients with newly diagnosed multiple myeloma.
Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple MyelomaJuly 17, 2017
Ixazomib, a new proteasome inhibitor (PI), is a third option for the treatment of relapsed/refractory multiple myeloma (RRMM) offering the potential of improved efficacy and the convenience of oral therapy.
Why is a type and crossmatch needed before starting patients on treatment with daratumumab (Darzalex)?
Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein demonstrated promising results.
The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.
Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.
MIT team develops simple, less painful diagnostic test for multiple myeloma using microfluidic chip and conventional blood sample.
In this review of the role of bortezomib in the treatment of multiple myeloma, the researchers explain what nurses need to watch for in patients taking this drug.
Carfilzomib significantly prolonged overall survival compared with bortezomib in patients with relapsed or refractory multiple myeloma.
Younger and usual adult body mass index (BMI) may be linked to increased risk for developing multiple myeloma, research indicates.
Sign Up for Free e-newsletters
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- In Older Women With Breast Cancer QoL May Predict 10-Year Mortality
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|